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glycemic control. To further improve outcomes for employees with diabetes and 
improve long-term cost-savings, employers might need to focus on programs that 
target medication adherence.
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OBJECTIVES: To elicit utility values associated with type 2 diabetes from Korean 
and Taiwanese populations and identify key drivers of preferences within these popu-
lations. Utility studies conducted in non-Asian populations often elicit preferences 
using a survey population or scaling method that is not preferred by Asian payers. As 
the use of pharmacoeconomics becomes more prevalent in Asia there is a greater need 
to understand implications of adapting overseas studies and to identify appropriate 
utility values when calculating cost utility ratios in the region. METHODS: A total 
of 132 study participants (67 from the general population and 65 type 2 diabetes 
patients) were recruited equally from Korea and Taiwan. Health states for type 2 
diabetic patients were adapted from a published UK study. Utilities for the health 
states were elicited using a chained standard gamble method (SG) and the EQ-5D. A 
paper SG was administered with multiple researchers assisting and verifying respon-
dents’ logic. Demographic data were collected. Analyses were conducted using 
approved methods and compared to published UK utility values. RESULTS: The mean 
utility of type 2 diabetes patients without complications was 0.937 (EQ-5D among 
patients). Asian patients indicated greater disutility from weight gain (0.0488 for 5% 
gain) and less utility from weight loss (0.0184 for 5% loss), which was similar to 
ﬁndings from the UK. The average disutility associated with gastrointestinal side 
effects was 0.07. CONCLUSIONS: Localized utility studies provide insight into the 
geographical preferences related to type 2 diabetes health states. The value placed 
upon weight loss versus weight gain, a respondent’s baseline BMI and differences in 
study design may drive variation in utilities between Asia and the UK. The ability to 
adapt utility studies conducted overseas to capture Asian preferences using methods 
preferred by Asian payers has meaningful implications for future cost utility studies 
conducted in Asia.
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OBJECTIVES: Recent advances in monoclonal antibody therapies offer the prospect 
of the prevention or amelioration of type 1 diabetes (T1DM). The present study was 
designed to capture UK preference weights for outcomes of infusion therapy for chil-
dren (8–12yrs); adolescents (13–17yrs) and adults. Such values could be used in a cost 
effectiveness analysis. METHODS: In-depth interviews were conducted with adults 
(n  4) and parents of children (n  4) and parents of adolescents (n  4) all with 
T1DM to characterise their quality of life. These data, plus an interview with a clinical 
expert and ﬁndings from a literature review were used to construct vignette descrip-
tions of health. Vignettes described T1DM; T1DM with reduced need for insulin; 
T1DM insulin free; receiving infusion therapy and receiving infusion therapy plus 
acute phase reaction(APR). Separate vignettes described adults, adolescents and chil-
dren. Following expert review of content validity, vignettes were rated (using the 
standard gamble interview) by the general public, adults with T1DM and parents of 
children with T1DM. Participants also the EQ-5D, PedsQL, and Hyperglycemic Fear 
Survey (data will be reported). Mixed model analyses were used to estimate the inﬂu-
ence on utility of different participant characteristics. RESULTS: Each health state 
was a signiﬁcant predictor of utility. The general public gave signiﬁcantly different 
utilities to the T1DM participants (p  .02). The utility gain associated with successful 
treatment was greater for the public versus T1DM group (reduced insulin 0.026 vs 
0.021, insulin-free 0.073 vs 0.057) and the disutility greater for undergoing infu-
sion therapy (on-infusion 0.114 vs 0.093, on-infusion with APR 0.159 vs 0.131). 
CONCLUSIONS: The general public and people with diabetes (or parents of children) 
all place signiﬁcant value on reducing the need for insulin injections, whilst recognising 
the disutility of undergoing infusion-based therapies. The differences between these 
groups may reﬂect adjustment and coping.
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OBJECTIVES: To investigate health related quality of life (HRQL) using EuroQol 
EQ-5D in patients with type 2 diabetes over the 24 months following insulin initiation. 
METHODS: INSTIGATE is a European prospective observational study investigating 
patients with type 2 diabetes initiating insulin during usual care. Follow-up data on 
resource use, treatment, clinical and patient reported outcomes over the 24 months 
following insulin initation were collected in Germany, Greece and Spain (N  564). 
RESULTS: Mean (SD) HbA1c was 9.4(1.72)% at insulin initiation, 7.2(1.03)% after 
6 months, and 7.2(1.07)% after 24 months. Only in Germany did mean HbA1c fall 
below 7%. Treatment approach varied; at baseline in Germany patients were pre-
scribed more intensive insulin regimens (mean 3.1 injections/day). In Greece and Spain 
most patients were prescribed either basal-only or premix-only with fewer mean daily 
injections (1.8 and 1.4 respectively). Across all patients at baseline, 14.5% reported 
problems with the EQ-5D self-care dimension, 37.9% reported problems with mobil-
ity and 31.4% with usual activities. In Greece, 68% of patients reported problems 
with anxiety/depression (overall: 54.1%); in Germany, 63% reported problems with 
pain/discomfort (overall: 52.3%). In the ﬁve dimensions, 62.4–80.3% of patients 
reported no change between baseline and 24 months, 10.4–16.1% reported worsening 
problems, and 8.6–22.9% reported improvement. Mean(SD) baseline EQ-5D visual 
analogue scale scores (VAS) were: Germany 65.7(19.07), Greece 64.8(19.24), Spain 
63(18.32). Patients in Greece saw the greatest and most sustained improvement in 
VAS; mean increase from baseline to 6 months 13.9(15.08) and baseline to 24 months 
11.9(17.82). In Germany and Spain increases from baseline to 6 months were 
12.4(16.5) and 4.6(17.69) respectively. From baseline to 24 months there was an 
increase of only 6.1(18.86) in Germany and 6.7(20.83) in Spain. CONCLUSIONS: 
Following insulin initiation there was an increase in HRQL (VAS) through 6 months, 
although this appeared to diminish between 6 and 24 months.
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OBJECTIVES: To explore the concept of the Minimum Clinically Important Difference 
(MID) of the Worry Scale of the Hypoglycaemia Fear Survey (HFS-II) and to quantify    
the clinical importance of different types of patient-reported hypoglycaemia. 
METHODS: An observational study was conducted in Germany with 392 patients 
with type 2 diabetes mellitus treated with combinations of oral anti-hyperglycaemic      
agents. Patients completed the HFS-II, the Treatment Satisfaction Questionnaire 
for Medication (TSQM), and reported on severity of hypoglycaemia. Distribution- 
and anchor-based methods were used to determine MID. In turn, MID was used to 
determine if hypoglycaemia with or without need for assistance was clinically meaning-
ful compared to having had no hypoglycaemia. RESULTS: 112 patients (28.6%) 
reported hypoglycaemic episodes, with 15 patients (3.8%) reporting episodes that 
required assistance from others. Distribution- and anchor-based methods resulted 
in MID between 2.1 and 5.8 and 3.6 and 3.9 for the HFS-II, respectively. Patients 
who reported hypoglycaemia with (21.6, 95% conﬁdence interval (CI) 15.1; 28.1)        
and without (12.1, 95% CI 9.7; 14.5) need for assistance scored higher on the    
HFS-II (range 0 to 72) than patients who did not report hypoglycaemia (6.0, 95% CI 
5.0; 7.0). CONCLUSIONS: We provide MID for HFS-II. Our ﬁndings indicate 
that the differences between having reported no hypoglycaemia, hypoglycaemia 
without need for assistance, and hypoglycaemia with need for assistance appear to be 
clinically important in patients with type 2 diabetes mellitus treated with oral anti-   
hyperglycaemic agents.
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OBJECTIVES: Adult Growth Hormone Deﬁciency (AGHD) is a poorly understood 
disease. As a result, treatment patterns and health care access vary by country and 
misunderstandings regarding the patient reported impacts are common. A well devel-
oped PRO measure identifying disease and treatment issues for this population and 
sensitive to treatment effects is critical for future research and clinical decision making. 
The purpose of the study was to understand the full spectrum of PRO issues in AGHD 
and develop a validation ready measure of these impacts. METHODS: As the ﬁrst 
phase of the PRO measure development process, qualitative data was collected from 
the literature, experts and patients and transcripts thematically coded according to 
grounded theory. Based on a synthesis of all information, a conceptual model of the 
impact of disease and treatment was developed and a PRO measure generated. 
RESULTS: 39 AGHD patients (7 focus groups, 3 telephone interviews) and 6 clinical 
experts in three countries (US, UK, Germany) were interviewed regarding the impact 
of AGHD and treatment on functioning, well-being and treatment burden. The mean 
age of patients was 50.7(range 23–82), mean age at diagnosis of 39.7 (range 4–71) 
and 87% were currently on treatment. Across countries common impacts were identi-
ﬁed in the domains of Energy, Physical Health, Psychological Health, Cognition and 
Treatment Burden. A conceptual model of the impacts of AGHD, their consequences 
and modiﬁers to the relationship was developed and a 46 item PRO impact measure 
(TRIM-AGHD) was generated with 5 discrete domains. The TRIM-AGHD was then 
cognitively debriefed in 9 patients and a validation ready version created. CONCLU-
SIONS: The instrument development process, the full conceptual model, and discus-
sion of clinical implications will be presented. This information should help clinicians 
identify key PRO issues for AGHD, facilitate targeted treatments and allow for 
meaningful measurement of treatment effect.
